Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02466243 · ClinicalTrials.gov registry record · Phase 2
Safety, Tolerability, and Efficacy of JBT-101 in Subjects With Dermatomyositis
A Phase 2 study, sponsored by Corbus Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 22
- Enrollment target
NCT02466243 is a Phase 2 study that was terminated before completion, run by Corbus Pharmaceuticals. The registered enrollment target is 22 participants.
The verdict
NCT02466243, a Phase 2 study, was terminated before completion, sponsored by Corbus Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 22 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety, tolerability and efficacy of JBT-101 in adult subjects with skin-predominant, dermatomyositis (DM) that is refractory to at least 3 months treatment with hydroxychloroquine.
Interventions
- DRUG Placebo
- DRUG JBT-101
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2015-06 |
| Est. Completion | 2021-01-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02466243
The ClinicalTrials.gov registry entry for NCT02466243 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Corbus Pharmaceuticals, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02466243 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02466243 about?
NCT02466243 is a clinical study titled "Safety, Tolerability, and Efficacy of JBT-101 in Subjects With Dermatomyositis". The purpose of this study is to evaluate the safety, tolerability and efficacy of JBT-101 in adult subjects with skin-predominant, dermatomyositis (DM) that is refractory to at least 3 months treatment with hydroxychloroquine.
What is the current status of trial NCT02466243?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2015-06. Estimated completion is 2021-01-29.
What interventions are being tested in trial NCT02466243?
The interventions under investigation include: Placebo (DRUG), JBT-101 (DRUG).
Who is sponsoring clinical trial NCT02466243?
This trial is sponsored by Corbus Pharmaceuticals, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.